Literature DB >> 15542391

Phenylalanine loading as a diagnostic test for DRD: interpreting the utility of the test.

R Saunders-Pullman1, N Blau, K Hyland, J Zschocke, T Nygaard, D Raymond, V Shanker, K Mohrmann, L Arnold, S Tabbal, D deLeon, B Ford, M Brin, S Chouinard, L Ozelius, C Klein, S B Bressman.   

Abstract

Phenylalanine loading has been proposed as a diagnostic test for autosomal dominant DRD (dopa-responsive dystonia), and recently, a phenylalanine/tyrosine (phe/tyr) ratio of 7.5 after 4 h was reported as diagnostic of DRD. To test the utility of this test in another sample with DRD, we administered an oral challenge of phenylalanine (100 mg/kg) to 11 individuals with DRD and one non-manifesting gene carrier. Only 6/12 had a 4 h phe/tyr ratio of greater than 7.5, suggesting that additional parameters must be set to avoid missing the diagnosis of DRD, including the need for the plasma phenylalanine to reach a minimum level 600 in order for the test to be valid. We propose that in cases where this minimum plasma phenylalanine level is not reached, plasma tetrahydrobiopterin should be measured or alternatively other symptomatic family members should be screened.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15542391     DOI: 10.1016/j.ymgme.2004.07.010

Source DB:  PubMed          Journal:  Mol Genet Metab        ISSN: 1096-7192            Impact factor:   4.797


  12 in total

1.  Urinary neopterin and phenylalanine loading test as tools for the biochemical diagnosis of segawa disease.

Authors:  Vincenzo Leuzzi; Claudia Carducci; Flavia Chiarotti; Daniela D'Agnano; Maria Teresa Giannini; Italo Antonozzi; Carla Carducci
Journal:  JIMD Rep       Date:  2012-04-18

2.  Screening for dopa-responsive dystonia in patients with Scans Without Evidence of Dopaminergic Deficiency (SWEDD).

Authors:  Anna De Rosa; Claudia Carducci; Carla Carducci; Silvio Peluso; Maria Lieto; Andrea Mazzella; Francesco Saccà; Vincenzo Brescia Morra; Sabina Pappatà; Vincenzo Leuzzi; Giuseppe De Michele
Journal:  J Neurol       Date:  2014-09-03       Impact factor: 4.849

Review 3.  Monoamine neurotransmitter disorders--clinical advances and future perspectives.

Authors:  Joanne Ng; Apostolos Papandreou; Simon J Heales; Manju A Kurian
Journal:  Nat Rev Neurol       Date:  2015-09-22       Impact factor: 42.937

Review 4.  Dopa-responsive dystonia--clinical and genetic heterogeneity.

Authors:  Subhashie Wijemanne; Joseph Jankovic
Journal:  Nat Rev Neurol       Date:  2015-06-23       Impact factor: 42.937

5.  Phenylalanine loading in pediatric patients with dopa-responsive dystonia: revised test protocol and pediatric cutoff values.

Authors:  Thomas Opladen; Jürgen G Okun; Peter Burgard; Nenad Blau; Georg F Hoffmann
Journal:  J Inherit Metab Dis       Date:  2010-07-29       Impact factor: 4.982

6.  Identification and functional characterization of phosphorylation sites on GTP cyclohydrolase I.

Authors:  Jianhai Du; Na Wei; Hao Xu; Ying Ge; Jeannette Vásquez-Vivar; Tongju Guan; Keith T Oldham; Kirkwood A Pritchard; Yang Shi
Journal:  Arterioscler Thromb Vasc Biol       Date:  2009-09-17       Impact factor: 8.311

7.  Sepiapterin reductase deficiency in a 2-year-old girl with incomplete response to treatment during short-term follow-up.

Authors:  K Kusmierska; E E W Jansen; C Jakobs; K Szymanska; E Malunowicz; D Meilei; B Thony; N Blau; J Tryfon; D Rokicki; E Pronicka; J Sykut-Cegielska
Journal:  J Inherit Metab Dis       Date:  2009-01-07       Impact factor: 4.982

8.  Validating the GTP-cyclohydrolase 1-feedback regulatory complex as a therapeutic target using biophysical and in vivo approaches.

Authors:  D Hussein; A Starr; L Heikal; E McNeill; K M Channon; P R Brown; B J Sutton; J M McDonnell; M Nandi
Journal:  Br J Pharmacol       Date:  2015-07-14       Impact factor: 8.739

Review 9.  Clinical spectrum of dopa-responsive dystonia and related disorders.

Authors:  Woong-Woo Lee; Beom Seok Jeon
Journal:  Curr Neurol Neurosci Rep       Date:  2014-07       Impact factor: 5.081

Review 10.  Clinical features and pharmacotherapy of childhood monoamine neurotransmitter disorders.

Authors:  J Ng; S J R Heales; M A Kurian
Journal:  Paediatr Drugs       Date:  2014-08       Impact factor: 3.022

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.